[1] 庹吉妤,张敏,郑荣寿,等.中国2014年胆囊癌发病与死亡情况分析[J].中华肿瘤杂志,2018,40(12):894-899.
[2] LAU C,ZYWOT A,MAHENDRARAJ K,et al.Gallbladder carcinoma in the united states:a population based clinical outcomes study involving 22,343 patients from the surveillance,epidemiology,and end result database (1973-2013)[J].HPB Surgery,2017,2017:1532835.
[3] SHUKLA S,SINGH G,SHAHI K,et al.Staging,treatment,and future approaches of gallbladder carcinoma[J].J Gastrointest Cancer,2018,49(1):9-15.
[4] APODACA-RUEDA M,CAZZO E,DE-CARVALHO R,et al.Prevalence of gallbladder cancer in patients submitted to cholecystectomy:experience of the University Hospital,Faculty of Medical Sciences,State University of Campinas-UNICAMP[J].Rev Col Bras Cir,2017,44(3):252-256.
[5] 于岚,何小东,武峤,等.胆囊癌发生相关危险因素的探讨[J].中华消化外科杂志,2012(5):433-436.
[6] 杨杰,何群,周军,等.胆囊癌危险因素的单中心回顾性分析[J].中国普通外科杂志,2018,27(8):939-944.
[7] LAM R,ZAKKO A,PETROV J,et al.Gallbladder disorders:a comprehensive review[J].Dis Mon,2021,67(7):101130.
[8] 宋彦伟,程军,罗威,等.胆囊息肉样病变直径对判断息肉性质的价值分析[J].实用肝脏病杂志,2020,23(1):130-133.
[9] 朱星屹.内镜微创保胆手术治疗胆囊良性疾病专家共识(2018版)[J].中国内镜杂志,2018,24(9):106-112.
[10] SCHNELLDORFER T.Porcelain gallbladder:a benign process or concern for malignancy?[J].J Gastrointest Surg,2013,17(6):1161-1168.
[11] KAMISAWA T,KANEKO K,ITOI T,et al.Pancreaticobiliary maljunction and congenital biliary dilatation[J].Lancet Gastroenterol Hepatol,2017,2(8):610-618.
[12] 王东,熊晓宇.胆囊癌的危险因素分析[J].中国普外基础与临床杂志,2019,26(3):270-275.
[13] SHARMA A,SHARMA K,GUPTA A,et al.Gallbladder cancer epidemiology,pathogenesis and molecular genetics:Recent update[J].World J Gastroenterol,2017,23(22):3978-3998.
[14] BAGHERLOU N,FARAJNIA S,ZAHRI S,et al.Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma[J].Caspian J Intern Med,2020,11(1):75-82.
[15] CHANG Y,CHANG M,HUANG K,et al.Clinicopathological and prognostic significances of EGFR,KRAS and BRAF mutations in biliary tract carcinomas in Taiwan[J].J Gastroenterol Hepatol,2014,29(5):1119-25.
[16] KASUGA A,SEMBA T,SATO R,et al.Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice[J].Cancer Sci,2021,112(5):1822-1838.
[17] HUANG W,TSAI C,CHAN C.Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma[J].J Formos Med Assoc,2017,116(6):464-468.
[18] HOADLEY K,YAU C,HINOUE T,et al.Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer[J].Cell,2018,173(2):291-304,e6.
[19] 陈善萍,王俊利,韦贵将.肿瘤分子标志物c-myc基因的研究进展[J].右江医学,2016,44(2):211-213.
[20] MA M,LI C,ZHANG Y,et al.Long non-coding RNA HOTAIR,a c-Myc activated driver of malignancy,negatively regulates miRNA-130a in gallbladder cancer[J].Mol Cancer,2014,13:156.
[21] LIU Y,LIU R,YANG F,et al.miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1[J].Mol cancer,2017,16(1):53.
[22] PSATHAS J,THOMAS-TIKHONENKO A.MYC and the art of microRNA maintenance[J].Cold Spring Harb Perspect Med,2014,4(8):a014175.
[23] LI H,JIN Y,HU Y,et al.The PLGF/c-MYC/miR-19a axis promotes metastasis and stemness in gallbladder cancer[J].Cancer Sci,2018,109(5):1532-1544.
[24] 周军,马捷.c-myc基因在侵袭性B细胞淋巴瘤中的研究进展[J].中华病理学杂志,2013,42(11):786-788.
[25] YANG D,ZHAN M,CHEN T,et al.miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer[J].Sci Rep,2017,7:43109.
[26] ARGON A,NART D,ORUÇ N,et al.The prognostic significance of clinicopathological features and apoptosis inhibitor proteins in pancreas ductal adenocarcinoma[J].Acta Gastroenterol Belg,2014,77(2):229-234.
[27] NIGAM J,CHANDRA A,KAZMI H,et al.Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer:a comparative study[J].Med Oncol,2014,31(9):167.
[28] YANG F,TANG Z,DUAN A,et al.NEAT1 long noncoding RNA upregulates survivin and facilitates gallbladder cancer progression by sponging microRNA-335[J].Onco Targets Ther,2020,13:2357-2367.
[29] MA A,TANG M,ZHANG L,et al.USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis[J].Oncogene,2019,38(13):2405-2419.
[30] 林卫国.ARAF基因沉默对胆囊癌恶性表型的影响[D].杭州:浙江大学,2019.
[31] ZEHIR A,BENAYED R,SHAH R,et al.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients[J].Nat Med,2017,23(6):703-713.
[32] 李卫峰,张景丽,陆中萃.胆囊癌、胆囊腺瘤性息肉和慢性胆囊炎组织中p53、β-catenin基因的表达及临床意义[J].临床和实验医学杂志,2018,17(4):391-394.
[33] LIN J,DONG K,BAI Y,et al.Precision oncology for gallbladder cancer:insights from genetic alterations and clinical practice[J].Ann Transl Med,2019,7(18):467.
[34] 卢晖,夏建兵,翁黎明,等.c-Myc、k-Ras、p16在胆囊癌细胞中的表达及临床意义[J].上海医药,2014,35(18):27-29.
[35] 张永杰,俞文隆.胆囊癌规范化诊治中外科手术的地位与价值[J].中国实用外科杂志,2016,36(10):1036-1040.
[36] YOON J,LEE Y,KIM S,et al.What is the better choice for T1b gallbladder cancer:simple versus extended cholecystectomy[J].World J Surg,2014,38(12):3222-3227.
[37] LEE S,JANG J,LIM C,et al.Systematic review on the surgical treatment for T1 gallbladder cancer[J].World J Gastroenterol,2011,17(2):174-180.
[38] WIDMANN B,WARSCHKOW R,BEUTNER U,et al.Effect of lymphadenectomy in curative gallbladder cancer treatment:a systematic review and meta-analysis[J].Langenbecks Arch Surg,2020,405(5):573-584.
[39] BAIU I,VISSER B.Gallbladder cancer[J].JAMA,2018,320(12):1294.
[40] 滕达,刘鹏,耿智敏,等.T1、T2期胆囊癌手术方式选择[J].中华肝脏外科手术学电子杂志,2021,10(1):24-28.
[41] SHINDOH J,DE ARETXABALA X,ALOIA T,et al.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer:an international multicenter study[J].Ann Surg,2015,261(4):733-739.
[42] 周迪,汤朝晖,全志伟.胆囊癌诊治中的若干问题及思考[J].中华外科杂志,2018,56(2):110-113.
[43] 何红莹,李广涛,李青利,等.T3期胆囊癌根治术的临床疗效及预后分析[J].中华消化外科杂志,2019,18(10):966-978.
[44] 王健东,全志伟.胆囊癌手术方式的选择与技术要点[J].中国实用外科杂志,2015,35(9):1022-1024.
[45] SHIRAI Y,WAKAI T,SAKATA J,et al.Regional lymphadenectomy for gallbladder cancer:rational extent,technical details,and patient outcomes[J].World J Gastroenterol,2012,18(22):2775-2783.
[46] KRELL R,WEI A.Gallbladder cancer:surgical management[J].Chin Clin Oncol,2019,8(4):36. |
